3billion Secures 300 Billion KRW in Post-IPO Funding to Accelerate Global AI Genetic Diagnostics Leadership

■ Financial Stability Secured via CPS and CB Mix; Focus on U.S. Insurance Market Entry and Expansion of Diagnostic Portfolio

■ 0% Surface and Maturity Interest Rates: Major Institutional Investors Including Kiwoom PE and GVA Asset Management Participate

■ Targeting 30 Million Rare Disease Patients in the U.S. and Diversifying Portfolio into Non-Symptomatic Screening Markets

SEOUL, South Korea — 3billion (CEO Chang-won Kum), an AI-driven rare disease diagnostics company, announced on the 23rd that it has secured 300 billion KRW in investment to drive global market expansion and secure future growth engines.

The funding consists of 17.5 billion KRW in Convertible Preferred Shares (CPS) and 12.5 billion KRW in Convertible Bonds (CB). Major domestic institutions with deep expertise in the bio and healthcare sectors, including Kiwoom Private Equity (PE), Kiwoom Securities, GVA Asset Management, IBK Industrial Bank of Korea, and Meritz Securities, participated in the round.

Notably, the issued CB was set with both surface and maturity interest rates at 0%. Successfully raising capital under zero-interest conditions despite the high-interest-rate environment is seen as a testament to the capital market’s overwhelming confidence in 3billion’s proprietary AI technology and future growth potential.

3billion plans to deploy the newly secured funds across three core growth pillars:

1. Infrastructure and Sales/Marketing Expansion in the U.S. Market
2. Expansion of Genetic Testing Services for Non-Symptomatic Individuals
3. Acceleration of Preclinical Validation for AI-driven Drug Discovery Pipelines

To accelerate growth in the United States, 3billion will aggressively recruit local experts, including laboratory engineers, clinical geneticists, and sales professionals. By targeting the U.S. rare disease market—which encompasses approximately 30 million people[i]—the company aims to secure high-value insurance reimbursements to drive both revenue growth and profitability.

Simultaneously, 3billion is diversifying its portfolio from patient diagnostics to screening for non-symptomatic individuals. Key initiatives include Whole Genome Sequencing (WGS)-based Genomic Newborn Screening (gNBS) and “Family Insight” testing. gNBS identifies treatable congenital disorders in newborns, while Family Insight identifies genetic causes for parents with a family history of genetic diseases or recurrent miscarriages. Through these offerings, 3billion aims to evolve into an AI genetic diagnostics company covering the entire human life cycle.

The company will also speed up the R&D of 15 pipelines discovered through its proprietary AI drug development platform. The funds will be used to accelerate experimental validation at the non-clinical and pre-clinical stages, increasing the potential for technology licensing-out (L/O) and joint development with global pharmaceutical companies.

“This investment serves as a solid foundation for 3billion to prove its overwhelming technological gap in the global genetic diagnostics market and achieve a quantum jump in growth,” said CEO Chang-won Kum. “By generating new revenue in the U.S. insurance market and expanding into non-symptomatic screening this year, we will solidify our position as a global leader in AI genetic diagnostics and enhance shareholder value.”

---

[i] Source: Yang, G. et al., “The national economic burden of rare disease in the United States in 2019”, Orphanet Journal of Rare Diseases (2022)